- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Tailored Treatments for Non-Segmental Vitiligo in a 38-Year-Old Male Patient
Author(s):
Rocco Serrao, MD, FAAD, discusses a case of a 38-year-old male with progressive vitiligo, exploring potential triggers and exacerbating factors, as well as lifestyle changes and treatment options to manage symptoms and improve quality of life.
Video Player is loading.
- What is your impression of this case?
- What challenges does this case present with, if any?
- Can you discuss any potential triggers or exacerbating factors that may have contributed to the onset and progression of vitiligo in this patient?
- Please comment on any lifestyle modifications or environmental changes that may help manage the symptoms and progression of vitiligo in this patient.
- What differential diagnoses would you consider for this patient and what steps would you complete to confirm this diagnosis?
- What are the key clinical features and diagnostic criteria used to diagnose vitiligo, and how do they differ from other hypopigmentary disorders?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Safety Considerations for IL-17 Inhibitors
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Related Content
